A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes (MIST2)

A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults

The primary objectives of this study are to assess the safety and feasibility of blood-stage controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers through experimental injection of cryopreserved P. vivax infected erythrocytes, and to choose the optimal inoculation dose for future P. vivax CHMI studies. In this study, blood-stage CHMI will be conducted in 8 volunteers per inoculum stock who will each be infected with P. vivax by experimental injection with cryopreserved P. vivax infected erythrocytes, which were collected from the controlled human Plasmodium vivax malaria infection model through experimental sporozoite infection in Thai adults (NCT04083508) . There are currently 2 stocks of inocula from 2 volunteers in the NCT04083508 study, which have differing quantities and stages of parasites.

The total number of volunteers of this study will be up to 16 (8 volunteers per inocula stock). The volunteers will be monitored closely as in-patients in the Hospital for Tropical Diseases, and will be treated according to the Research Proposal.

This study is funded by the UK Wellcome Trust. The grant reference number are Oxford/MORU: 212336/Z/18/Z and 212336/Z/18/A, and Mahidol University: 212336/A/18/Z and 212336/A/18/A.

Study Overview

• Status: Recruiting
• Conditions: Plasmodium Vivax Infection
• Intervention / Treatment: Biological: An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum; Biological: An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum; Biological: An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum; Biological: An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum

Detailed Description

This study is a blood-stage P. vivax human challenge study with the primary aim of assessing the safety and feasibility of a challenge model using two banks of cryopreserved P. vivax infected erythrocytes produced from NCT04083508 study to identify the dose of the inocula to be used in the future CHMI studies.

Sixteen healthy Thai adults, aged between 18 and 55 years will be recruited at the Clinical Therapeutics Unit (CTU) in the Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok. The overall period of each volunteer's participation will be 13 months: 2-week screening process prior to the Day 0 challenge, about 2-week inoculum process until reaching malarial treatment criteria, and follow-up period for 1 year after malarial treatment. All inclusion and exclusion criteria will be checked to ensure eligibility criteria have been met prior to Day 0.

Volunteers will be admitted to the hospital one day prior to challenged day. All eligible volunteers will have physical examinations. Serum pregnancy test (women only), malaria diagnosis, complete blood count (CBC), and biochemistry will be tested. Glucose -6-phospate dehydrogenase (G6PD) test and malaria immunological profiles will be tested for baseline information.

On the challenged day (Day 0), four different doses of inoculum (one whole vial,1:5 dilution, 1:10 dilution, and 1:20 dilution) will be assessed. Each dose of inoculum will be tested in 2 volunteers to identify the lowest concentration producing a reliable infection within a practicable timeframe. Therefore, there will be 8 volunteers enrolled per inoculum bank.

The assessment will be repeated in each inoculum bank. There are 2 inoculum banks so 16 volunteers will be enrolled into this study.

From Day 1 after challenge, the volunteers will be assessed once daily until malaria qPCR becomes positive. The assessment includes a clinical well-being check, physical examination, vital signs, and blood drawn for parasitaemia (malaria blood film, qPCR, and gametocyte qPCR) and membrane feeding to assess the transmissibility of gametocyte. Malaria immunology and CBC will be performed on day 4 and the day that qPCR become positive.

After qPCR becomes positive the monitoring of clinical well-being will continue. Blood will be drawn twice daily to monitor blood parasitaemia and allow membrane feeding to assess the transmissibility of gametocyte. Malaria immunology, CBC, and blood biochemistry will be performed on day that volunteer reach malaria treatment criteria.

When the malaria slide positivity and/or symptoms thresholds have been reached study physician will immediately prescribe antimalarial treatment with chloroquine according to local standard guidelines. Blood will be collected to test for malaria (blood films and qPCR) once daily until clinically recovered and two consecutive malaria blood films are negative (completing of the chloroquine treatment course) and volunteers will be discharged from the hospital.

If any volunteer reaches day 21 post-challenge without a positive malaria blood film, they shall be started on 3-day course of antimalarial treatment (chloroquine).

If a volunteer withdraws/is withdrawn from the study after challenge but before reaching the criteria for malaria treatment, then a complete, appropriate, curative course of antimalarial therapy must be completed

After discharge from the hospital, there will be out-patient visits on day 7, 28, 60, 90, 180, and 1 year post antimalarial treatment initiation. Blood will be collected to detect malaria parasites by blood film and qPCR, and for malaria gametocyte qPCR, membrane feeding assays (MFA), malaria immune response, CBC, and biochemistry according to the study protocol.

Data analysis

The safety of the CHMI will be assessed by descriptive analysis of the frequency, incidence and nature of adverse events and serious adverse events arising during the study. Since this is a feasibility study conducted in 2 volunteers per dosing group, formal statistical hypothesis testing will not be used for most analyses due to the limited sample size, and only a brief Statistical Analysis Plan (SAP) will be developed and finalized prior to database lock.

The study will be conducted in accordance with the current approved protocol, the International Conference on Harmonisation-Good Clinical Practice (ICH GCP), relevant regulations, and standard operating procedures. Data will be evaluated for compliance with the protocol and accuracy in relation to source documents. Following written standard operating procedures, the monitors will verify that the clinical study is conducted and data are generated, documented and reported in compliance with the protocol.

• Study Type: Interventional
• Enrollment (Estimated): 16
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Nicholas Day, MD; Phone Number: 2020 +66 (0)2 354 9170; Email: nickd@tropmedres.ac
• Study Contact Backup: Name: Jetsumon Sattabongkot Prachumsri, Ph.D; Phone Number: 2022 +66 (0)2 354 9100; Email: jetsumon.pra@mahidol.ac.th

Study Locations

• Thailand
  • Bangkok, Thailand, 10400
    • Recruiting
    • Faculty of Tropical Medicine
    • Contact: Borimas Hanboonkunupakarn, MD; Phone Number: +66 (0)8 6 9705705; Email: borimas@tropmedres.ac
    • Contact: Podjanee Jittamala, MD; Phone Number: +66 (0)8 1956 3371; Email: podjanee@tropmedres.ac

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

The volunteer must meet all of the following criteria to be eligible for the study:

1. Healthy Thai adult aged 20 to 55 years with weight at least 50 kg.
2. Red blood cells positive for the Duffy antigen/chemokine receptor (DARC)
3. Women only: Must practice continuous effective contraception for the duration of study period until 3 months post-challenge.
4. Agreement to refrain from blood donation during the course of the study and for 1 year after the initiation of antimalarial treatment.
5. Willing to be admitted in the Hospital for Tropical Diseases for clinical monitoring, until antimalarial treatment is completed and their symptoms are settling.
6. Willing to take a curative antimalarial treatment following CHMI.
7. Willing to reside in Bangkok and its vicinity for 2 months after malarial treatment initiation.
8. Able to read and write in Thai.
9. Provide written informed consent to participate in the trial
10. Answer all questions on the informed consent quiz correctly
11. Educational level: has at least an undergraduate degree

Exclusion Criteria:

The volunteer must NOT enter the study if any of the following apply:

1. Positive malaria qPCR OR malaria film
2. Presence of any medical condition (either physical or psychological) which in the judgment of the investigator would place the participant at undue risk or interfere with the results of the study (e.g. serious underlying cardiac, renal, hepatic or neurological disease; severe malnutrition; congenital defects or febrile condition)
3. Presence of chronic disease or chronically use of medication
4. Use of systemic antibiotics with known antimalarial activity in the 30 days before challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin)
5. Use of immunoglobulins or blood products (e.g. blood transfusion) at any time in the 1 year preceding enrolment
6. Receipt of an investigational product, any vaccine in the 30 days preceding enrolment (D0), or planned receipt during the study period
7. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data or the P. vivax parasite as assessed by the Investigator.
8. Any confirmed, or suspected immunosuppressive, or immunodeficient state, including HIV infection, asplenia, history of splenectomy, recurrent, severe infections, and chronic infection
9. Immunosuppressant medication within the past 6 months preceding enrolment (D0) (inhaled and topical steroids are allowed)
10. History of allergic disease or reactions likely to be exacerbated by malaria infection
11. Female participant who is pregnant as evidenced by positive beta-human chorionic gonadotropin (β-HCG) test, lactating, or planning pregnancy during the course of the study
12. Contraindications to the use of antimalarial treatment (e.g. chloroquine, atovaquone / proguanil or dihydroartemisinin/piperaquine)
13. Use of medications known to have a potentially clinically significant interaction with the antimalarial drug that will be used in this study (chloroquine, atovaquone / proguanil or dihydroartemisinin/piperaquine)
14. Known existing positive family history in both 1st AND 2nd degree relatives < 50 years old for cardiac disease
15. History of cardiac arrhythmia, including clinically relevant bradycardia
16. Family history of congenital QT prolongation or sudden death
17. Any clinical condition, including using medications, known to prolong the QT interval.
18. Screening electrocardiogram (ECG) demonstrates a QT interval corrected for heart rate (QTc) ≥ 450 ms.
19. Suspected or known or history of alcohol abuse
20. Suspected or known or history of drug abuse.
21. Concurrently participating in another clinical study, at any time during the study period
22. Haemoglobin < 11 g/dL
23. Positive hepatitis B surface antigen or seropositive for hepatitis C virus
24. Positive vector-borne diseases (dengue, chikungunya, zika, Japanese encephalitis, filaria)

25. Finding on safety laboratory values as defined below:

    • Abnormal AST (AST > 40 U/L for male, and > 32 U/L for female [upper normal range])
    • Abnormal ALT (ALT > 41 U/L for male, and > 33 U/L for female [upper normal range])
    • Abnormal serum creatinine (Scr) (Creatinine [Cr] > 1.17 mg/dL for male, and > 0.95 mg/dL for female [upper normal range])
    • Abnormal blood urea nitrogen (BUN 6-20 mg/dl [normal range])
    • Abnormalities corrected calcium and magnesium blood levels
26. Blood group Rhesus negative
27. Blood incompatibility to the inoculum
28. Positive for coronavirus disease 2019 (COVID-19)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Challenge with whole dose blood-stage inoculum (neat); Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL	Biological: An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum; An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)
Experimental: Challenge with 1:5 dilution blood-stage inoculum; 1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.	Biological: An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum; An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum
Experimental: Challenge with 1:10 dilution blood-stage inoculum; 1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.	Biological: An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum; An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum
Experimental: Challenge with 1:20 dilution blood-stage inoculum; 1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.	Biological: An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum; An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incident of treatment-emergent adverse events of blood-stage controlled human P. vivax malaria infection	Measured by (serious) adverse event (AE) occurrences	Through study completion, over one year
Choosing the optimal inoculation dose for future P. vivax CHMI studies, which will be the lowest concentration that produces a reliable infection within a comparable timeframe as compare to the highest concentration.	The optimal inoculation dose for future P. vivax CHMI studies, which will be the lowest concentration that produces a reliable infection within a comparable timeframe as compare to the highest concentration	Through study completion, over one year
Feasibility of primary P. vivax blood-stage CHMI, as measured by successful infection (development of detectable persistent parasitaemia by thick blood film +/- clinical symptoms)		Through study completion, over one year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric mean and standard deviation/error of Pvs25 gene transcript copy number/microL at each time point	Measured by qPCR in experimental P. vivax infection through blood-stage challenge	Challenge day; day 1 to 5 or up to day of treatment and during subsequent days of follow-up through study completion, over one year
Transmissibility of gametocytes from the infected volunteer to Anopheles mosquito vector	Measured by gametocytes from the infected volunteer to Anopheles mosquito vector using Membrane feeding assay	Through study completion, over one year
Cellular Immune response to primary P. vivax infection (frequencies, percentages (%), and expression level of mononuclear cells)	Immune cells including Innate and adaptive immune cells react and express during the PV infection (profile and frequency)	Day-1, Day 2, Day 5, Day of blood donation, DayRx7, DayRx28, DayRx90, DayRx1 year
Level of antibodies and cytokines responses to primary P. vivax infection during different phase of infection	Immune cells defense PV antigen by determining the level of antibody response and inflammatory cytokine	Day-1, Day 2, Day 5, Day of blood donation, DayRx7, DayRx28, DayRx90, DayRx1 year

Collaborators and Investigators

• Sponsor: University of Oxford
• Collaborators: Wellcome Trust
• Investigators: Principal Investigator: Nicholas Day, MD, University of Oxford

Publications and helpful links

General Publications

• Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013 Jan;26(1):36-57. doi: 10.1128/CMR.00074-12.
• Rahimi BA, Thakkinstian A, White NJ, Sirivichayakul C, Dondorp AM, Chokejindachai W. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J. 2014 Dec 8;13:481. doi: 10.1186/1475-2875-13-481.
• Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):79-87.
• Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440. doi: 10.1371/journal.pntd.0006440. eCollection 2018 Apr.
• Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013 Jun 20;12:212. doi: 10.1186/1475-2875-12-212.
• Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013 Oct 3;369(14):1381-2. doi: 10.1056/NEJMc1301936. No abstract available.
• Grabowsky M. The billion-dollar malaria moment. Nature. 2008 Feb 28;451(7182):1051-2. doi: 10.1038/4511051a. No abstract available.
• Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. Lancet. 2013 Nov 23;382(9906):1700-1. doi: 10.1016/S0140-6736(13)62238-2. Epub 2013 Nov 14. No abstract available.
• Mueller I, Shakri AR, Chitnis CE. Development of vaccines for Plasmodium vivax malaria. Vaccine. 2015 Dec 22;33(52):7489-95. doi: 10.1016/j.vaccine.2015.09.060. Epub 2015 Oct 1.
• Payne RO, Griffin PM, McCarthy JS, Draper SJ. Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol. 2017 Feb;33(2):141-150. doi: 10.1016/j.pt.2016.11.001. Epub 2016 Dec 10.
• Keith JA, Agostini Bigger L, Arthur PA, Maes E, Daems R. Delivering the promise of the Decade of Vaccines: opportunities and challenges in the development of high quality new vaccines. Vaccine. 2013 Apr 18;31 Suppl 2:B184-93. doi: 10.1016/j.vaccine.2012.12.032.
• Pronker ES, Weenen TC, Commandeur H, Claassen EH, Osterhaus AD. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755. doi: 10.1371/journal.pone.0057755. Epub 2013 Mar 20.
• Knezevic I, Moorthy V, Sheets R. WHO consultation on clinical evaluation of vaccines, 17-18 July 2014, WHO Headquarters, Geneva, Switzerland. Vaccine. 2015 Apr 21;33(17):1999-2003. doi: 10.1016/j.vaccine.2015.01.056. Epub 2015 Mar 4.
• Stanisic DI, McCarthy JS, Good MF. Controlled Human Malaria Infection: Applications, Advances, and Challenges. Infect Immun. 2017 Dec 19;86(1):e00479-17. doi: 10.1128/IAI.00479-17. Print 2018 Jan.
• Roestenberg M, Hoogerwerf MA, Ferreira DM, Mordmuller B, Yazdanbakhsh M. Experimental infection of human volunteers. Lancet Infect Dis. 2018 Oct;18(10):e312-e322. doi: 10.1016/S1473-3099(18)30177-4. Epub 2018 Jun 18.
• Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, Silk SE, Biswas S, Miura K, Roberts R, Rampling TW, Venkatraman N, Hodgson SH, Labbe GM, Halstead FD, Poulton ID, Nugent FL, de Graaf H, Sukhtankar P, Williams NC, Ockenhouse CF, Kathcart AK, Qabar AN, Waters NC, Soisson LA, Birkett AJ, Cooke GS, Faust SN, Woods C, Ivinson K, McCarthy JS, Diggs CL, Vekemans J, Long CA, Hill AV, Lawrie AM, Dutta S, Draper SJ. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. J Infect Dis. 2016 Jun 1;213(11):1743-51. doi: 10.1093/infdis/jiw039. Epub 2016 Feb 4. Erratum In: J Infect Dis. 2016 Sep 15;214(6):978.
• McCarthy JS, Griffin PM, Sekuloski S, Bright AT, Rockett R, Looke D, Elliott S, Whiley D, Sloots T, Winzeler EA, Trenholme KR. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis. 2013 Nov 15;208(10):1688-94. doi: 10.1093/infdis/jit394. Epub 2013 Aug 1.
• Griffin P, Pasay C, Elliott S, Sekuloski S, Sikulu M, Hugo L, Khoury D, Cromer D, Davenport M, Sattabongkot J, Ivinson K, Ockenhouse C, McCarthy J. Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Negl Trop Dis. 2016 Dec 8;10(12):e0005139. doi: 10.1371/journal.pntd.0005139. eCollection 2016 Dec.
• Collins KA, Wang CY, Adams M, Mitchell H, Robinson GJ, Rampton M, Elliott S, Odedra A, Khoury D, Ballard E, Shelper TB, Lucantoni L, Avery VM, Chalon S, Moehrle JJ, McCarthy JS. A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions. J Clin Invest. 2020 Jun 1;130(6):2920-2927. doi: 10.1172/JCI134923.
• Odedra A, Mudie K, Kennedy G, Watts RE, Rossignol E, Mitchell H, Gower J, Rebelo M, Pava Z, Pawliw R, Woolley S, Lalloo DG, Robinson G, Lynch S, Collins KA, Amante F, McCarthy J. Safety and feasibility of apheresis to harvest and concentrate parasites from subjects with induced blood stage Plasmodium vivax infection. Malar J. 2021 Jan 14;20(1):43. doi: 10.1186/s12936-021-03581-w.
• Robinson S, Harris A, Atkinson S, Atterbury C, Bolton-Maggs P, Elliott C, Hawkins T, Hazra E, Howell C, New H, Shackleton T, Shreeve K, Taylor C. The administration of blood components: a British Society for Haematology Guideline. Transfus Med. 2018 Feb;28(1):3-21. doi: 10.1111/tme.12481. Epub 2017 Nov 6. No abstract available.

Study record dates

Study Major Dates

• Study Start (Actual): May 23, 2022
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: July 28, 2021
• First Submitted That Met QC Criteria: October 6, 2021
• First Posted (Actual): October 7, 2021

Study Record Updates

• Last Update Posted (Actual): July 19, 2023
• Last Update Submitted That Met QC Criteria: July 18, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: controlled human malaria infection; Plasmodium Vivax Infection
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Vector Borne Diseases; Parasitic Diseases; Protozoan Infections; Infections; Communicable Diseases; Malaria
• Other Study ID Numbers: MAL21001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Volunteer's data and results from blood analyses stored in our database may be shared with other researchers to use in the future. However, the other researchers will not be given any information that could identify the subject.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No